Dr Reddys Laboratories Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Dr Reddys Laboratories Ltd filed with BSE on 15 Jul 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Dr. Reddy's held a call to disclose that an impurity was found out of specification during testing of a scaled-up semaglutide API batch used to make the finished injectable formulation, prompting a halt to commercial supply pending investigation and revalidation. Management said no product already supplied to the market is affected, no regulatory filings are impacted, and the oral tablet formulation using a different API source is unaffected. The company said it expects to resume commercial supply around November, targeting 6 to 7 million pens between November and March against a prior annual target of 12 million pens.
Numbers mentioned
Semaglutide pen supply target: 6-7 million pens (Q3-Q4 FY27 / November to March)
p. 3
“and will be on track to supply, hopefully, 6-7 million pens between Q3 and Q4 of FY27.”
Erez Israeli, page 3 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Semaglutide commercial supply resumption — resume commercial supply · late October, early November
stated conditionally by Erez Israeli
p. 4
“Which means that the actual supply to the market can resume, let's say, late October, early November, something like that.”
Erez Israeli, page 4 of the filed PDF · View the filing
Validation and process timeline — complete validation batches · end of September
stated conditionally by Erez Israeli
p. 4
“should take us somewhere around September. If this will happen, I will tell you after that the risk of that, but if this will happen, it means that commercial API scale can come to OneSource during October”
Erez Israeli, page 4 of the filed PDF · View the filing
Alternate injectable supplier qualification — pre-approval supplement for backup supplier · about one year
stated firmly by Erez Israeli
p. 5
“It means that we are about one year away, give or take, because you normally need to submit it as a pre-approval supplement”
Erez Israeli, page 5 of the filed PDF · View the filing
EBITDA margin target — 20% plus EBITDA margin
stated firmly by Erez Israeli
p. 6
“So we are on the same pace and nothing has changed beside this event.”
Erez Israeli, page 6 of the filed PDF · View the filing
Captive manufacturing facility plans — proceed with own facility alongside OneSource · a few months later than originally communicated
stated firmly by Erez Israeli
p. 13
“Just will take a few more months later than we originally communicated, in anticipation.”
Erez Israeli, page 13 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management estimated validation completion around September and market supply resuming around November, while flagging risk of further delay.
Answered by Erez Israeli
Asked by Damayanti Kerai: What is the timeline for resolving the issue and does the 6-7 million pen supply target still hold?
p. 4
“if this will happen, it means that commercial API scale can come to OneSource during October, and then they can make the product.”
Erez Israeli, page 4 of the filed PDF · View the filing
Management said there is no recall since affected material never shipped, but supply will be halted until validation is complete.
Answered by Erez Israeli
Asked by Damayanti Kerai: Was the issue contained to few batches and will there be a product recall or a complete halt?
p. 5
“So, there will be a halt of supply between now and September.”
Erez Israeli, page 5 of the filed PDF · View the filing
Management confirmed no submission or prior approval is required since there is no change to specifications.
Answered by Erez Israeli
Asked by Neha Manpuria: Will validation require any regulatory resubmission to authorities like Canada?
p. 5
“Doesn't require any prior approval from any agency.”
Erez Israeli, page 5 of the filed PDF · View the filing
Management said a backup supplier would require a pre-approval supplement taking about a year, so it would not help in the near term.
Answered by Erez Israeli
Asked by Neha Manpuria: How soon could an alternate supplier be added as backup for injectables?
p. 5
“So, we do have a backup. It's not the same supplier. But this will require a pre-approval supplement.”
Erez Israeli, page 5 of the filed PDF · View the filing
Management said batches associated with the issue would likely need to be written down.
Answered by Erez Israeli
Asked by Dr. Bino Pathiparampil: Would inventory at OneSource need to be written down?
p. 6
“We may need to write down the batches that were associated with that. Probably, yes.”
Erez Israeli, page 6 of the filed PDF · View the filing
Management said the target remains unchanged but the missed sales volume will be a downside versus earlier discussions.
Answered by Erez Israeli
Asked by Dr. Bino Pathiparampil: How does this impact the targeted 20%+ EBITDA margin?
p. 6
“Obviously, we will miss to sell certain quantities in this period of time, so obviously this will be a downside of what we have discussed in May and June, when we met you guys.”
Erez Israeli, page 6 of the filed PDF · View the filing
Management said existing Canadian supply is unaffected, but future supply will be impacted by the delay.
Answered by Erez Israeli
Asked by Surya Patra: Has this impacted supply already sent to the Canadian market?
p. 7
“So the answer is no, whatever we send to the Canadian market will not get impacted.”
Erez Israeli, page 7 of the filed PDF · View the filing
Management attributed the issue to the process and reaction in API manufacturing, not equipment.
Answered by Erez Israeli
Asked by Tushar Manudhane: Is the impurity related to raw material, process, or equipment?
p. 7
“It is to do with the process and the reaction of the API.”
Erez Israeli, page 7 of the filed PDF · View the filing
Management said no regulatory notification is needed and that internal R&D, supplemented by external help, is investigating.
Answered by Erez Israeli
Asked by Kartik Mehta: What milestone should be tracked toward September resolution and is external help being used?
p. 8
“So first, Kartik, there is no need to inform any agencies. There is no change of specs or change of regulatory filing.”
Erez Israeli, page 8 of the filed PDF · View the filing
Management said demand remains strong and unaffected, with supply being the constraint.
Answered by Erez Israeli
Asked by Shyam Srinivasan: Has demand changed such that the 6-7 million pen guidance still holds despite the delay?
p. 10
“Nothing has changed. Unfortunately, if we had 15 million, we could supply that also.”
Erez Israeli, page 10 of the filed PDF · View the filing
Management said no penalties are anticipated, though some arrangements involving down payments may need renegotiation.
Answered by Erez Israeli
Asked by Abdulkader Puranwala: Will the supply delay trigger failure-to-supply fees or penalties with partners?
p. 13
“So, there are no penalties as such, potentially, and it was not under discussion, I just want to give you my assessment.”
Erez Israeli, page 13 of the filed PDF · View the filing
Risks flagged
Risk of further delay if revalidation is unsuccessful
p. 5
“Is there a risk that we can fail again? Always. There is confidence, but naturally there is a risk of a further delay.”
Erez Israeli, page 5 of the filed PDF · View the filing
Halt of commercial supply until process revalidation is complete
p. 5
“And if the process is not validated, we cannot send quantities to OneSource, and that's what created a halt of supply.”
Erez Israeli, page 5 of the filed PDF · View the filing
Possible write-down of inventory batches associated with the issue
p. 6
“We may need to write down the batches that were associated with that. Probably, yes.”
Erez Israeli, page 6 of the filed PDF · View the filing
Shortfall versus previously communicated sales volumes due to lost months of supply
p. 6
“Obviously, we will miss to sell certain quantities in this period of time, so obviously this will be a downside of what we have discussed in May and June, when we met you guys.”
Erez Israeli, page 6 of the filed PDF · View the filing
Possible loss of partners to alternative suppliers during the supply gap
p. 12
“If they will choose to do to a different partnership or to go elsewhere, we'll obviously respect it.”
Erez Israeli, page 12 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.